Exactech Inc.
http://www.exac.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exactech Inc.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Remibrutinib REMIXes The Itch Record
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.
Trials In Focus: Patient Advocacy Group Takes Trial Diversity To Capitol Hill
The Foundation for Sarcoidosis Research briefed US Congress on participation by Black patients in sarcoidosis and other rare disease trials. Also, the US FDA issued a draft guidance on psychedelic drug trials; Insilico is taking its AI-discovered IPF drug into Phase II; and Compugen and Jasper dosed patients in their oncology trials.
Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market
Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.
Company Information
- Industry
- Distributors
- Contract Manufacturing Organization
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Blue Ortho SAS
- Exactech Australia Pty Ltd
- TPG Capital
- XpandOrtho, Inc.
- Exactech Italia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice